Racivir
Appearance
![]() | |
Clinical data | |
---|---|
Routes of administration | Investigational |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
NIAID ChemDB | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C8H10FN3O3S |
Molar mass | 247.24 g·mol−1 |
3D model (JSmol) | |
| |
|
Racivir is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Pharmasset for the treatment of HIV.[1] It is the enantiomer of emtricitabine, a widely used NRTI, meaning that the two compounds are mirror images of each other.
![](http://upload.wikimedia.org/wikipedia/commons/thumb/6/67/Emtricitabine_skeletal.svg/220px-Emtricitabine_skeletal.svg.png)
References
- ^ "Racivir". AIDSmeds.com. March 24, 2006. Archived from the original on 2014-01-02. Retrieved March 21, 2008.